Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London Summit - Slideshow

Sutro Biopharma presented its latest advancements at the 16th Annual World ADC London Summit in February 2026, showcasing proprietary antibody-drug conjugate (ADC) technologies. The company highlighted its cell-free protein synthesis platform, which accelerates ADC development by enabling precise engineering of complex biologics without traditional cell-based limitations. Key focus areas included clinical progress of lead candidates, particularly STRO-002 for ovarian cancer and STRO-001 for multiple myeloma, with updated trial data shared during the event. Sutro emphasized partnerships with major pharma firms to expand its ADC pipeline, leveraging its platform’s scalability and customization capabilities for next-generation therapies. The presentation underscored Sutro’s strategic push to advance ADCs as a cornerstone of targeted cancer treatment, aligning with industry trends toward precision oncology solutions.